Paper19251545
A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature.
Sun HY and 5 others. J Formos Med Assoc, 2009. Cited by 24 papers, by iCite.
Cite this record
ConductScience Library. A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature. Papers, record 19251545. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19251545
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antitubercular Agents | Major topic |
| Hepatitis | Major topic |
| Tuberculosis | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Causality | |
| Comorbidity | |
| Female | |
| Humans | |
| Incidence | |
| Male | |
| Middle Aged | |
| Prospective Studies | |
| Risk Factors | |
| Taiwan | |
| Young Adult |
Source PubMed
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 19933035 | Prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature. | https://conductscience.org/library/papers/19933035 | PubMed |
| Comment in | 22248841 | Hepatitis during antituberculosis treatment. | https://conductscience.org/library/papers/22248841 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42809079 | HBV/HCV coinfection and anti-tuberculosis drug-induced liver injury: from risk assessment and exploration of mechanisms to preventive considerations. | Eur J Clin Microbiol Infect Dis | 2026 | https://conductscience.org/library/papers/42809079 | PubMed |
| 34698694 | Clinical characteristics and outcomes of drug-induced liver injury in Taiwan: With emphasis on the impact of chronic hepatitis B infection. | J Chin Med Assoc | 2022 | https://conductscience.org/library/papers/34698694 | PubMed |
| 29340497 | Tuberculosis treatment. | J Bras Pneumol | 2017 | https://conductscience.org/library/papers/29340497 | PubMed |
| 28224437 | Baseline HBV load increases the risk of anti-tuberculous drug-induced hepatitis flares in patients with tuberculosis. | J Huazhong Univ Sci Technolog Med Sci | 2017 | https://conductscience.org/library/papers/28224437 | PubMed |
| 27516382 | Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. | Clin Infect Dis | 2016 | https://conductscience.org/library/papers/27516382 | PubMed |
| 26833347 | Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. | BMC Infect Dis | 2016 | https://conductscience.org/library/papers/26833347 | PubMed |
| 26767859 | Early monitoring for detection of antituberculous drug-induced hepatotoxicity. | Korean J Intern Med | 2016 | https://conductscience.org/library/papers/26767859 | PubMed |
| 26106962 | Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment. | Clinics (Sao Paulo) | 2015 | https://conductscience.org/library/papers/26106962 | PubMed |
| 25595441 | Hepatotoxicity from antituberculous therapy in the elderly: a systematic review. | Tuberculosis (Edinb) | 2015 | https://conductscience.org/library/papers/25595441 | PubMed |
| 25525805 | Impact of glutathione S-transferase M1 and T1 on anti-tuberculosis drug-induced hepatotoxicity in Chinese pediatric patients. | PLoS One | 2014 | https://conductscience.org/library/papers/25525805 | PubMed |
| 24897928 | The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study. | BMC Infect Dis | 2014 | https://conductscience.org/library/papers/24897928 | PubMed |
| 24292367 | Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis. | Lung | 2014 | https://conductscience.org/library/papers/24292367 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19251545
GET https://conductscience.org/api/papers/v1/19251545/authors